Associations of Regional Body Fat With Risk of Cardiovascular Disease and Mortality Among Individuals With Type 2 Diabetes
AbstractObjectives. We aimed to prospectively examine the association between regional body fat and risk of cardiovascular disease (CVD) in individuals wit
Higher arm fat percentage was linearly associated with increased CVD risk, whereas higher trunk fat percentage was nonlinearly associated with increased CVD risk.
The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
Source : https://www.mdpi.com/1420-3049/29/6/1236
Type 2 diabetes mellitus is a multifactorial disorder whose primary manifestation usually initiates with elevated blood sugar levels. Several antidiabetic agents are used to manage type 2 diabetes mellitus, of...
Coadministration of grapefruit with empagliflozin should be cautiously monitored and avoided because grapefruit elevates the plasma level of empagliflozin.
Patients with systemic lupus erythematosus and lupus nephritis showed significantly higher risk of hypertension, hyperlipidemia, and type 2 diabetes compared with those without lupus nephritis.
This synopsis focuses on outpatient management of diabetes with high risk of hypoglycemia; the guideline also addresses prevention of hypoglycemia in hospitalized patients.
Incidence of Type 2 Diabetes, Cardiovascular Disease and Chronic Kidney Disease in Patients With Multiple Sclerosis Initiating Disease-Modifying Therapies: Retrospective Cohort Study Using a Frequentist Model Averaging Statistical Framework
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300708
Researchers are increasingly using insights derived from large-scale, electronic healthcare data to inform drug development and provide human validation of novel treatment pathways and aid in drug repurposing/repositioning. The objective...
A positive but nonsignificant trend was observed among patients treated with dimethyl fumarate toward a decreased incidence of type 2 diabetes, CVD, and CKD relative to other disease-modifying therapies.